Researchers found the hormone FGF21 can reverse obesity in mice and may help develop new treatments for obesity and MASH in humans. It targets hindbrain regions, boosting energy burning instead of suppressing appetite like GLP-1 drugs. FGF21 acts on the nucleus of the solitary tract and area postrema, which communicate with the parabrachial nucleus to drive its metabolic effects.